Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 20.83% year-over-year to $54.9 million; the TTM figure through Mar 2026 stood at $54.9 million (up 20.83% YoY), while the FY2025 annual figure was $57.8 million, down 3.87% from the prior year.
• Other Non-Current Assets was $54.9 million for Q1 2026 at Amneal Pharmaceuticals, down from $57.8 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $108.3 million in Q3 2022 to a low of $36.3 million in Q3 2024.
• Historically, Other Non-Current Assets has averaged $68.8 million across 5 years, with a median of $63.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets soared 454.39% in 2022, then plunged 59.26% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $103.2 million in 2022, then tumbled by 46.21% to $55.5 million in 2023, then climbed by 8.31% to $60.1 million in 2024, then retreated by 3.87% to $57.8 million in 2025, then declined by 5.06% to $54.9 million in 2026.
• The last three Other Non-Current Assets figures came in at $54.9 million (Q1 2026), $57.8 million (Q4 2025), and $39.5 million (Q3 2025), per Business Quant data.